As all eyes turn to Astra’s camizestrant, a sneak peek at Arvinas’s data suggests that ARV-471 might not be competitive.
Two Astrazeneca breast cancer projects record apparent pivotal successes in settings where Roche had failed.
All-comer Serd studies in pretreated breast cancer look doomed, so why do Astra and Lilly persist? And why isn’t Radius seizing its advantage?
Giredestrant fails, but the group hopes for better luck in earlier therapy lines.
Amcenestrant flunks the long-delayed Ameera-3 trial in ER-positive Her2-negative breast cancer, so how much blame can be put on poor study design?
Trial design comes into focus as late-stage readouts loom for Sanofi, Roche and Astrazeneca.